Artwork

Inhalt bereitgestellt von Jon Chee. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Jon Chee oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschĂŒtztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!

🧬 David Li - Meliora Therapeutics - Part 4 | Mechanism Identification in Biotech | AI & ML in Drug Development | Creating a New Method for Drug Discovery | Fundraising for Meliora | Building a Foundational Startup Team

28:15
 
Teilen
 

Manage episode 428387618 series 3461709
Inhalt bereitgestellt von Jon Chee. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Jon Chee oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschĂŒtztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.

Part 4 of 4.

My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.

Before Meliora, David was Chief Business Officer at Everest Detection, an early detection liquid biopsy startup, and led commercial operations at Benchling, a life sciences software platform valued at $6 billion with over $500 million in funding.

David started his career in Goldman Sachs Healthcare Investment Banking Group and KKR's Private Equity Group, advising and investing in transactions exceeding $10 billion. His diverse financial and life sciences background offers valuable insights for founders.

Join us this week and hear about:

  • David’s transition from private equity to co-founding Meliora and using AI/ML in drug development
  • His fundraising experiences for Meliora and current outlook on the fundraising landscape in 2024
  • His advice for aspiring entrepreneurs and reflections on “thinking big” in biotech
  • Identifying mischaracterized mechanisms of action and establishing Meliora as a drug development company and computational platform

Please enjoy my conversation with David Li.
Timestamps:
00:28 Intro
02:00 Jason Scheltzer identifies mechanisms of action, the beginnings of Meliora
05:08 David meets Jason Scheltzer, forming Meliora with a thesis, as David becomes founding CEO and initial fundraising begins
07:20 David’s serendipitous meeting with Jason, getting on board as more than an investor
09:16 Building the early founding team at Meliora, establishing Meliora as a drug company
12:05 How Meliora is disrupting the status quo in drug discovery and development
17:24 David’s approach to building an internal pipeline and BD partnerships
19:49 David’s experience fundraising and his outlook on fundraising in 2024
22:21 Meloria’s 2-year vision, transitioning from Seed to Series A
24:03 Shoutouts and advice to 21-year old self
26:23 Outro

Find Our Guest, David Li, at these links:

Find Our Host, Jon Chee, at these links:

Social & Website

Enriched Notes:

Topics Mentioned:
Drug candidates that were mischaracterized https://ergobio.substack.com/p/meliora-therapeutics-is-building

People Mentioned:
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
  continue reading

88 Episoden

Artwork
iconTeilen
 
Manage episode 428387618 series 3461709
Inhalt bereitgestellt von Jon Chee. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Jon Chee oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschĂŒtztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.

Part 4 of 4.

My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.

Before Meliora, David was Chief Business Officer at Everest Detection, an early detection liquid biopsy startup, and led commercial operations at Benchling, a life sciences software platform valued at $6 billion with over $500 million in funding.

David started his career in Goldman Sachs Healthcare Investment Banking Group and KKR's Private Equity Group, advising and investing in transactions exceeding $10 billion. His diverse financial and life sciences background offers valuable insights for founders.

Join us this week and hear about:

  • David’s transition from private equity to co-founding Meliora and using AI/ML in drug development
  • His fundraising experiences for Meliora and current outlook on the fundraising landscape in 2024
  • His advice for aspiring entrepreneurs and reflections on “thinking big” in biotech
  • Identifying mischaracterized mechanisms of action and establishing Meliora as a drug development company and computational platform

Please enjoy my conversation with David Li.
Timestamps:
00:28 Intro
02:00 Jason Scheltzer identifies mechanisms of action, the beginnings of Meliora
05:08 David meets Jason Scheltzer, forming Meliora with a thesis, as David becomes founding CEO and initial fundraising begins
07:20 David’s serendipitous meeting with Jason, getting on board as more than an investor
09:16 Building the early founding team at Meliora, establishing Meliora as a drug company
12:05 How Meliora is disrupting the status quo in drug discovery and development
17:24 David’s approach to building an internal pipeline and BD partnerships
19:49 David’s experience fundraising and his outlook on fundraising in 2024
22:21 Meloria’s 2-year vision, transitioning from Seed to Series A
24:03 Shoutouts and advice to 21-year old self
26:23 Outro

Find Our Guest, David Li, at these links:

Find Our Host, Jon Chee, at these links:

Social & Website

Enriched Notes:

Topics Mentioned:
Drug candidates that were mischaracterized https://ergobio.substack.com/p/meliora-therapeutics-is-building

People Mentioned:
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
  continue reading

88 Episoden

Alle Folgen

×
 
Loading …

Willkommen auf Player FM!

Player FM scannt gerade das Web nach Podcasts mit hoher QualitĂ€t, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos gerĂ€teĂŒbergreifend zu synchronisieren.

 

Kurzanleitung